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Abstract
Background: Self-administration of medicines by patients whilst in hospital is being increasingly promoted despite
little evidence to show the risks and benefits. Pain control after total knee replacement (TKR) is known to be poor.
The aim of the study was to determine if patients operated on with a TKR who self-medicate their oral analgesics
in the immediate post-operative period have better pain control than those who receive their pain control by
nurse-led drug rounds (Treatment as Usual (TAU)).
Methods: A prospective, parallel design, open-label, randomised controlled trial comparing pain control in patient-
directed self-management of pain (PaDSMaP) with nurse control of oral analgesia (TAU) after a TKR. Between July 2011
and March 2013, 144 self-medicating adults were recruited at a secondary care teaching hospital in the UK. TAU patients
(n = 71) were given medications by a nurse after their TKR. PaDSMaP patients (n= 73) took oral medications for analgesia
and co-morbidities after two 20 min training sessions reinforced with four booklets. Primary outcome was pain (100 mm
visual analogue scale (VAS)) at 3 days following TKR surgery or at discharge (whichever came soonest). Seven patients did
not undergo surgery for reasons unrelated to the study and were excluded from the intention-to-treat (ITT) analysis.
Results: ITT analysis did not detect any significant differences between the two groups’ pain scores. A per protocol (but
underpowered) analysis of the 60% of patients able to self-medicate found reduced pain compared to the TAU group
at day 3/discharge, (VAS -9.9 mm, 95% CI -18.7, − 1.1). One patient in the self-medicating group over-medicated but
suffered no harm.
Conclusion: Self-medicating patients did not have better (lower) pain scores compared to the nurse-managed patients
following TKR. This cohort of patients were elderly with multiple co-morbidities and may not be the ideal target group
for self-medication.
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Background
The effectiveness of the self-administration of medica-
tion (SAM) in the hospital setting has recently been
reviewed [1]. It was concluded that “few studies of high
methodological quality using validated outcome mea-
sures exist. Inconsistencies in both measuring and
reporting outcomes across studies make it challenging to
compare results and draw substantive conclusions about
the effectiveness of SAM schemes”. Following a total
knee replacement (TKR) operation, patients experience
substantial pain but there is debate as to the best way to
manage it [2, 3]. Poor pain control following a TKR can
prevent early mobilisation, which substantially raises the
risk of patients developing deep-vein thrombosis [4] and
can reduce range of motion [5].
This study investigated if a patient’s level of pain and
satisfaction with care might be influenced by who is in
control of the analgesic medications i.e. whether it is
patient-directed self-management of pain (PaDSMaP) or
under nurse control (treatment as usual (TAU)). Self-
medicating may allow the patient to have more control and
take the analgesia “by the clock” [6] but also allow them to
vary their analgesia according to pain and activity levels [7].
Traditionally patient controlled analgesia (PCA) has
often involved patients being in control of intravenous
programmable pumps delivering opioid medications [8].
These have been shown to reduce pain levels by approxi-
mately 13 mm (95% CI – 20 to - 6) on a 100 mm VAS at
49–72 h after surgery [8]. They also have very high levels
of patient satisfaction [8]. The programmable pump
prevents overdoses by locking the patient out after a max-
imum dose is delivered over a given time period. However
the disadvantage of this method of analgesia delivery is
that a patient is “tied” to an intravenous pump, and so is
less likely to mobilise freely. Additionally the patient is
only in control of a single analgesic medication. Optimum
post-surgical analgesia requires a combination of
analgesics. The addition of non-opioid analgesics (para-
cetamol, non-steroidal anti-inflammatory drugs, or anti-
convulsants such as gabapentin) to an opioid regimen has
been shown to improve quality of analgesia and reduce
opioid use [9–11].
Our study aimed to investigate whether patients who
were in control of all of their oral analgesics experienced
lower levels of pain compared to TAU. The primary
objective was to investigate if PaDSMaP reduces pain at
3 days or on discharge, whichever is sooner, after
primary TKR operation compared to TAU. Secondary
objectives investigated whether the PaDSMaP and TAU
groups differ in terms of;
 Overall pain levels and pain on mobilization.
 Patient satisfaction with the management of
their pain.
 Satisfaction with pain management information
provided.
 More global outcomes, such as quality of life (QOL)
and activities of daily living (ADLs).
 Time to mobilization, and whether time to
mobilization is associated with frequency of adverse
events, and improvements in ADLs, QOL and pain
at 6 weeks after the operation.
 Incidence of adverse events.
 Quantity and type of pain medications used whilst
inpatients.
Methods
Study registration
The trial was registered at the Clinical Trials Registry
with the International Standard Randomised Controlled
Trials Number (ISRCTN10868989) in March 2012.
Patient recruitment commenced in August 2011 before
registration due to an oversight of the trial team. It had
been assumed that it had been registered earlier. The
purpose and method of the research were explained to the
patients at the pre-admission clinic about 2 weeks prior to
their operation when written consent was obtained. The
study protocol was published in Trials [12]. The
CONSORT checklist is available in Additional file 1.
Study design and study population
We conducted a prospective, parallel design, open label,
randomised controlled, superiority trial of patient-
directed self-management of pain (PaDSMaP) compared
with nurse control of oral analgesia (TAU) after a total
knee replacement [12]. Participants were recruited from
the Norfolk & Norwich University Hospital, a secondary
care teaching hospital in the United Kingdom.
Competent adults were recruited from patients waiting
to undergo a unilateral total knee replacement. The key
inclusion criterion was that these patients were able to
manage their medications at home. They also had to be
English-speaking and literate. We excluded patients that
were; opiate-tolerant, opiate-dependent or using modified-
release opiate preparations, or had a history of drug or alco-
hol abuse within the last 5 years. The reasoning for this was
that patients who have an established opiate tolerance
might be expected to need to continue on an equivalent
opiate regimen to prevent opiate withdrawal, and may also
require more opiate to ensure equivalent analgesia, and
thus would not be comparable to the rest of the population.
Other exclusion criteria included expecting post-operative
intensive care, or were not competent by reason of de-
mentia or other cause. Post-operatively patients had to be
awake and breathing independently, and able to answer
questions and follow commands (i.e. competent). Patients
were expected to require standard step 1–3 oral analge-
sics, the 48 patients that received regional blocks or
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epidural analgesia, started PaDSMaP or TAU as soon as
they began oral analgesia. These inclusion and exclusion
criteria were in line with the hospital’s drug self-
administration policy [13].
The research nurses checked patient eligibility and
consent against a checklist. Patients were allocated a
personal 6-digit ‘PIN’ identifier that allowed them access
to the independent telephone randomisation service at
the Clinical Trials Unit (CTU) at the University of East
Anglia (UEA). On entry of a valid PIN, the system gen-
erated a unique Study Code and randomly allocated the
patients to either the PaDSMaP or TAU arm of the trial.
The study code and allocation was sent in an email to
the research team and stored in the trial database on the
secure CTU server at UEA.
A computer generated randomisation list allocated the
patients in a 1:1 ratio to PaDSMaP or TAU groups.
Randomisation was unstratified. Patients were allocated
in randomly distributed blocks of four and six. The
patients were randomised, assessed and trained in the
pre-operative clinic or at their homes. Patients, their
clinical team and the research team were all aware of
their allocation. As the intervention was under the con-
trol of the patients and the primary outcome (pain VAS)
was a patient-reported measure it was impossible to
blind patients or clinical staff as to participant’s alloca-
tion. It was originally planned to blind the statistician to
allocation but as we accidentally included information
on duration of self-medication in the statistician’s
database they were unblinded, however the analysis plan
was pre-specified and approved in a blinded fashion and
therefore any potential bias was minimised.
Study interventions
All participants received the TKR information sheet that
is provided as standard to everyone undergoing the op-
eration (Additional file 2). All participants received a
study information sheet which informed them that they
would be randomised to one of two groups, and in
which the two groups’ protocols were described in detail
(but this did not include the training pamphlets pro-
vided to the self-medicating group once they had been
allocated). Care was taken to emphasise the lack of
evidence to prefer one protocol over the other. These in-
formation sheets are provided in Additional files 3 and 4.
The majority of patients recruited to this study (78%)
received the Modified Caledonian Technique (MCT)
Norwich Enhanced Recovery Programme (NERP) [14].
This programme aims to enhance the recovery of
patients having primary knee replacements by a multi-
modal programme, which facilitates early mobility and
discharge [15]. The NERP focuses on the provision of
safe and effective analgesia with minimal side-effects,
which enables early mobility. The analgesia protocol
combined a number of classes of analgesics (Table 1).
Individual patients were always offered the most suitable
protocol for their particular circumstances, so some pa-
tients did not follow the NERP protocol. This did not
prove an obstacle; as such variations were allowed by our
protocol and recorded. Once on the ward TAU patients
received their medications as usual from the nurses.
The PaDSMaP package [12] was developed by members
of the research team in conjunction with relevant clinical
and lay experts. This resulted in a comprehensive, struc-
tured, evidence-based training manual delivered in four
pamphlets [3, 16, 17] (Additional file 5). Patients were
given these pamphlets in a 20 min training session at the
pre-operative clinic outlining why pain control is impor-
tant, what medications they were likely to be using and
how to take them, the common side effects and their
management, and non-pharmacological methods for pain
relief (e.g. ice packs).
Consultation with lay representatives and healthcare
professionals highlighted that it would be inconsistent to
allow self-medicating patients to be in control of their
oral analgesia but not their oral co-morbid medications.
Therefore if patients were prescribed medications for
their co-morbidities they were usually in control of
these. In general no specific training was provided re-
garding these medications as patients were expected to
have sufficient knowledge to take them appropriately.
However patients on anti-hypertensive or anti-coagulant
medications were specifically warned to check with
nursing staff that it was appropriate for them to take
these medications after the operation.
Patients were assessed by a nurse for their competency
to manage their own medications, by checking patients
were orientated as to location and time, and that they
could remember and follow simple instructions [13]. Pa-
tients were then given a pack of 14 days-worth of their
medications (co-morbid medications and analgesics)
previously prepared by the ward pharmacists. All partici-
pants received the medications prescribed to them by
their clinical team (their consultant, the pain team, and
orthopaedic pharmacists).
The UK’s Misuse of Drugs Act (1971) aims to pre-
vent high risk “controlled” medications from being
misused, obtained illegally or causing harm. The legis-
lation places legal requirements on the method of
prescribing and dispensing of controlled medications.
Due to these requirements, any patients prescribed
controlled medications (irrespective of their alloca-
tion) received them direct from the nurses as they
were not approved for self-medication protocols at
the hospital [13]. In practice this mostly affected the
oxycodone prescribed as part of the standard NERP
analgesic protocol. The trial medications were stored
in trial-specific lockable bedside cabinets. Patients
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were given the keys on a lanyard and asked to keep
the cabinet locked when not in use and the keys se-
cure. Patients recorded their medication usage on the
standard drug chart. This chart had been prepared by
the ward pharmacists so that all text was in block
capitals, and no abbreviations (e.g. tds) were used.
The ward nurses and pharmacists conducted their
usual checks of medication usage and record keeping
as well as patient competency at the usual drug
rounds.
Ward staff (nurses, physiotherapists and the pain
team) were trained by the research team about the pur-
pose of the study, the information that the patients
would receive and how to assess competency of partici-
pants to self-medicate after the operation.
Baseline measures
At baseline we measured a number of factors in order
to provide a description of the characteristics of our
sample. Some of these have been identified by other
studies as factors that can affect post-operative pain
and recovery, and so were possible confounders
(Tables 2, 3, 4) [18–23]. Baseline measures were
recorded in pre-operative outpatient clinics or in
patient’s homes.
Outcomes
The primary outcome was pain levels at discharge or
after 3 days post-operatively (whichever was the
sooner), using a non-graded 100 mm VAS [24]. The
pain VAS was anchored by the words “No pain” to
“Worst pain” and referred to static pain levels over
the last 4 h in the knee that underwent surgery. The
primary outcome was measured on the inpatient ward
after surgery.
Secondary outcome measures for the patients were:
 Pain levels; static and after mobilisation (3 times
a day for days 1–3) and static pain at 6 weeks.
Pain VAS were recorded at mealtimes as these
were relatively stable in the ward setting; Breakfast
08:00, Lunch 13:00, Supper 17:45. Pain after
mobilisation scores related to pain at that moment.
 Satisfaction with pain levels (SWP), medication
usage (Days 1–3 and 6 weeks).
Table 1 Range of analgesics provided to patients after the surgery
Analgesic Usual dose Notes
Paracetamol 1 g four times a day NERP
Ibuprofen 400 mg three times a day NERP If patient is able to tolerate
Gabapentin 300 mg twice a day NERP
Oxycodone 10-20 mg twice a day NERP doses (Daily EOMD 20–40). Controlled
drug so must be delivered by nurse.
Oxycodone 2.5-10 mg as required Non-NERP doses. Controlled drug so must be
delivered by nurse.
Oramorph (liquid morphine
sulphate)
5-20 mg as required up to every 2 h NERP (Daily EOMD 5–240). For breakthrough pain.
Zomorph (morphine sulphate capsules) 10-20 mg twice a day (Daily EOMD 20–40)
Codeine 30-60 mg four times a day or as required (Daily EOMD 18–36)
Dihydrocodeine 30-60 mg four times a day or as required (Daily EOMD 12–24)
Co-codamol 8/500, 1–2 tablets, once a day or as required
30/500, 2 tablets, four times a day or as required
(Daily EOMD 1.2–2.4) (Daily EOMD 36)
Co-dydramol 10/500, 2 tablets, four times a day (Daily EOMD 8)
Tramadol 50-100 mg four times a day or as required (Daily EOMD 20–40)
Aspirin 75 mg once a day Given as an anticoagulant
Intramuscular morphine 5-10 mg as required NERP (Daily EOMD 5–10). For escape analgesia.
Not part of the self-medicating protocol as
delivered by injection.
Intravenous morphine 5-50 mg as required (Daily EOMD 5–50) Not part of the self-medicating
protocol as delivered by injection.
Ropivicaine 0.2% 140-200 ml Not part of the self-medicating protocol as delivered
by periarticular injection.
Bold text rows indicate the medications and dosages recommended for use by the NERP protocol
Abbreviations: NERP Norwich Enhanced Recovery Protocol, EOMD Equivalent Oral Morphine Dose
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 Satisfaction with Information About Medicines Scale
(SIMS) [25] (Day 3 or at discharge (if sooner) and
6 weeks).
 Quality of life (using the EQ-5D-3 L) [26, 27], Activities
of daily living (using the Oxford Knee Score (OKS))
[28],and a modified version of the client services receipt
inventory to assess health-related costs (6 weeks) [29].
 Time to mobilisation was measured from the time
the patient returned to the ward after the operation
to the time they managed their first transfer out of
the bed.
 Adverse events up to 6 weeks were extracted from
patient notes.
We planned to investigate medication usage but realised
that the high level of variation in the individualised anal-
gesic protocols after surgery (see Table 1) meant that direct
comparison between the two groups was impossible.
Table 2 Baseline characteristics
TAU
n = 69 unless stated
PaDSMaP
n = 68 unless stated
All
n = 137 unless stated
Male 43.5% (30/69) 42.6% (29/68) 41.6 (59/137)
Age (Years) 69.7 (7.5) 70.0 (8.7) 69.8 (8.1)
BMI 32.5 (4.5) 31.5 (5.2) 32.0 (4.9)
Current Smoker 5.9% (4/68) 4.4% (3/68) 5.1% (7/136)
Race 100% Caucasian 100% Caucasian 100% Caucasian
After School Education 55.1% (38/69) 54.4% (37/68) 54.7 (75/137)
Degree education 29.4% (20/68) 32.8% (22/67) 31.1% (42/135)
Employed 15.9% (11/69) 27.9% (19/68) 21.9% (30/137)
Retired 78.3% (54/69) 67.6% (46/68) 73.0% (100/137)
Other 5.8% (4/69) 4.4% (3/68) 5.1% (7/137)
Availability of assistance on discharge? 91.3%(63/69) 86.8%(59/68) 89.1%(122/137)
Presence of stairs at discharge home? 62.3%(43/69) 63.2%(43/68) 62.8%(86/137)
Previous knee op 21.7% (15/69) 22.1% (15/68) 21.9% (30/137)
Previous hip replacement 8.7% (6/69) 7.4% (5/68) 8.0% (11/137)
Duration knee pain (years)a 5 (1–66) 3 (1–27) 3 (1–66)
ASA Grade 2 or 3 95.6% (66/69) 95.5% (63/66) 95.6% (129/135)
Other musculoskeletal problems 8.7% (6/69) 26.5% (18/68) 17.5% (24/137)
No. prescriptionsa 6 (1–17) 6 (0–14) 6 (0–17)
Takes NSAIDS? 52.2% (n = 36/69) 59.1% (n = 39/66) 55.6% (75/135)
Number of Comorbiditiesa 3 (0–10) 3 (0–9) 3 (0–10)
% HADS Depressed (≥8) aMedian(range) 17.4% (12/69) 3 (0–16) 7.5% (5/67) 3 (0–11) 12.5% (17/136) 3 (0–16)
% HADS Anxious (≥ 8) aMedian (range) 14.5% (10/69) 4 (0–13) 17.9% (12/67) 3 (0–13) 16.2% (22/136) 4 (0–13)
NERP protocol implemented 75% (52/69) 82% (54/67) 78% (106/136)
Note: excludes the 7 post randomisation exclusions (but includes 2 withdrawals)
% (x/n) or mean (sd) unless ain which case it was median (range)
Abbreviations: ASA American Society of Anesthesiologists, BMI body mass index, HADS Hospital Anxiety and Depression Scale, NSAIDs non-steroidal anti-inflamma-
tory drugs, PaDSMaP Patient-directed self-management of pain, TAU treatment as usual
Table 3 Baseline Beliefs about Medicines Questionnaire: subscale totals
Beliefs about Medicines Questionnaire: TAU
n = 69 unless stated
PaDSMaP
n = 68 unless stated
All
n = 137 unless stated
Specific Needs 17.4 (4.5) n = 64 17.8 (5.1) n = 63 17.6 (4.8) n = 127
Specific Concerns 13.3 (4.1) n = 64 11.2 (4.0) n = 63 12.3 (4.2) n = 127
General Overuse 11.2 (2.6) n = 63 10.3 (3.0) n = 63 10.7 (2.9) n = 126
General Harm 9.7 (2.4) n = 63 9.2 (2.7) n = 63 9.4 (2.6) n = 126
Abbreviations: PaDSMaP Patient-directed self-management of pain; TAU treatment as usual
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Secondary measures were measured in the inpatient
ward for the 3 days after surgery, and at an outpatient
clinic for the 6 week data.
A qualitative evaluation and cost-effectiveness analysis
were also undertaken and are reported in detail else-
where [30].
The qualitative evaluation found that patients had a
positive experience of self-medicating even for those
patients who reported an initial poor experience of pain
control. Some patients reported feeling “isolated” and “a
bit concerned I was taking their (nurses) jobs away”. Every
patient when asked if they had the option to self-medicate
for a similar operation responded positively. Healthcare
professionals expressed positive views about the empower-
ing nature of self-medication but had realistic concerns
about capacity, documentation and accountability. The
paternalistic nature of healthcare was evident (Balls P,
Darrah C, Deane KHO, Gray R, Swift L, Barton G, et al:
Patient self-management of pain (PaDSMaP); a qualitative
investigation of the acceptability of self-medicating with
oral analgesics in the context of a randomised controlled
trial following total knee replacement, Unpublished quali-
tative data from this trial).
The cost effectiveness analysis [30] showed that the
self-medicating intervention cost £307 to deliver. However
most of the costs (£243) were due to set-up costs such as
the purchase of bedside cabinets and printing costs. The
mean incremental cost for the self-medication group was
calculated to be £774 (95%CI £174 to £1374) (when ad-
justed for age (ns), gender (ns), education (ns) and
baseline cost (ns) based on 133 observations, Adj R-
squared = 0.0983). However, much of this incremental cost
was accounted for by four self-medicating patients who
needed intensive care for extended periods of time (for rea-
sons unrelated to the self-mediation protocol). The mean
incremental QALY gain was small, 0.002 (95%CI –0.002 to
0.006) (adjusted for age (ns), gender (ns), education (ns)
and baseline EQ-5D (p < 0.001) based on 133 observations,
Adj R-squared = 0.7225). This leads to a mean cost per
quality of life adjusted year (QALY) of > £390,000 [30].
Sample size calculation
Seventy-two patients in each arm was calculated to be suf-
ficient to detect a between-group difference of 0.5
standard deviations in the VAS pain intensity with 80%
power using an independent samples t-test. Dahlen [5] re-
ported a standard deviation in VAS pain intensity score of
24 mm 2–5 days after total knee arthroplasty so assuming
similar variability this represents a difference of about
12 mm which is within the range of minimum clinically
important differences (MCID) that have been reported for
pain VAS measures [31, 32]. However, the study was for-
mally powered to detect a difference of 0.5 standard devia-
tions which is therefore the definition of MCID formally
used. Calculations used a significance level of 0.05. A
drop-out rate of 10% was expected and accounted for.
Statistical analysis
Linear regression models were used to compare primary
and secondary outcomes between the intervention and
control. There is no single ‘right’ way of selecting covari-
ates for adjustment. In particular Pocock [33] says that
‘pre-specification of all covariates for adjustment’ while
‘desirable in principle, is often unachievable in practice’
due to ‘inadequate prior knowledge as to which baseline
factors are related to prognosis’. This was the case in
this study as many factors have been proposed to affect
post-operative pain levels [18, 19, 22]. Thus Pocock [33]
advocates ‘defining objective variables selection algo-
rithms’ a priori to ‘overcome any suspicions that post
hoc selection of covariates might be based on subjective
criteria’. Therefore as planned in our original protocol
[15], we finalised our analysis plan 6 months before the
final data being available, identifying baseline variables
which differed between the groups (i) and a set of candi-
date covariates supplied by the research team (ii) in line
with current research [18, 19, 22]. Therefore estimates
were also obtained, (i) adjusted by baseline VAS,
Hospital Anxiety and Depression Scale (HADS) anxiety
and depression scores and (ii) by further potential cova-
riates. (Variables which gave P < 0.10 when examined in-
dividually as a predictor of the primary outcome,
adjusting for variables in (i), were included in a multiple
predictor model and then eliminated one by one until all
potential predictors had P < 0.10); this resulted in further
adjustment by gender and number of prescribed medica-
tions. The assumptions of the models were checked
Table 4 Baseline values of outcomes
TAU
n = 69 unless stated
PaDSMaP
n = 68 unless stated
All
n = 137 unless stated
EQ5D-3 L 0.450 (0.29) 0.463 (0.27) 0.457 (0.28)
Pain VAS (pain over last 4 h) 52.9 (22.3) 48.5 (23.8) 50.8 (23.0)
Oxford Knee Score 18.8 (7.2) 19.0 (7.1) 18.9 (7.1)
Satisfaction with Pain 8.1 (2.5) 8.9 (2.3) 8.5 (2.4)
Abbreviations: EQ5D-3 L EuroQOL, 3 level; PaDSMaP Patient-directed self-management of pain; TAU – treatment as usual; VAS – pain visual analogue scale
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using residual analysis which found no outliers or heav-
ily influential observations.
The main analysis was conducted on an ITT basis. For
a per protocol analysis successful self-medication was
defined as those who started self-medicating and were
continuing at 72 h/discharge, even if they stopped for a
period during the hospital stay.
Linear regression models were used to investigate, for
those randomised to the self-medication group, which
baseline variables individually predicted successful self-
medication. In order to account for repeated measures,
mixed linear regression models were used to compare
series of VAS scores measured at breakfast, lunch and
supper over the 72 h follow up period, between groups.
In the light of the results, unplanned analyses used the
same methods to additionally adjust by day 1 breakfast
static VAS scores. SPSS v18 was used for the analysis.
The number of co-morbidities was compared between
Fig. 1 Flow diagram of participants through the trial
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individual included and excluded from the per-protocol
analysis using a Mann-Whitney test.
Results
Trial flow and baseline characteristics
Between July 2011 and March 2013, 144 competent
adults about to undergo a primary unilateral TKR were
recruited (Fig. 1). Patients without co-morbidities
(American Society of Anesthesiologists (ASA) grade 1)
[34] were generally sent to a private healthcare provider
not involved in this study (n = 448). Of the 665 patients
screened for eligibility for the RCT 23% were excluded
because they were not managing their own medications
at home (usually due to dementia). A further 28%
refused to participate, often because they felt unsure of
their ability or desire to self-medicate after a major
operation.
Seventy-one patients were randomly allocated to TAU,
and 73 to the PaDSMaP group. However seven patients
(five PaDSMaP, two TAU) did not undergo surgery for
reasons unrelated to the study and were excluded them
from the ITT analysis. The remaining patients (n = 137)
are characterised in Tables 2, 3, 4. They had a median of
three co-morbidities in addition to their osteoarthritis.
The HADS assessment determined that 13% of patients
scored above the cut off for depression, and 17% scored
above the cut off for anxiety. Twenty-four patients (18%)
had musculoskeletal diagnoses other than osteoarthritis,
of which the most common were rheumatoid arthritis
(22%) or fibromyalgia (15%).
Half of patients were not taking any opiates prior to
their surgery (Table 5). Of those participants prescribed
opiates for after their operation, the majority (57 of 68,
84%) were prescribed a single opiate usually to be taken
as required (50 of 57, 88%). The maximum prescribed
Equivalent Oral Morphine Dose (EOMD) [35] was 96,
but most patients were taking substantially lower
dosages. It was not possible to calculate the EOMD ac-
curately for each patient due to the variability in the
usage of “as required” medication.
The Beliefs about Medicines Questionnaire (BMQ)
assesses commonly held beliefs about medicine [21].
Table 5 Preoperative opiates
Opiate Doses Number of PaDSMaP patients Number of TAU patients Maximum daily EOMD
None – 34 35 –
Codeine 15 mg as required 0 1
30-60 mg four times a day 0 2 36
30-60 mg as required 6 3
Co-codamol 8/500, 2 tablets, once, twice or three
times a day
2 4 7.2
8/500 as required 1 2
15/500 as required 1 1
30/500, 2 tablets, once, three or four
times a day
3 5 36
30/500 as required 6 12
Dihydrocodeine 30 mg once a day 0 1 3
30 mg as required 1 1
60 mg once, twice or four times a
day
3 2 24
Co-dydramol 10/500, 1–2 tablets, three or four
times a day
1 2 8
10/500 as required 5 6
30/500 as required 0 1
Tramadol 50 mg once, three or four times a day 0 3 20–40
50 mg as required 1 3
100 mg twice or four times a day 1 1 40–80
100 mg as required 1 3
Tramadol paracetamol 37.5/500, 2 tablets, as required 1 0
Oramorph (liquid
morphine sulphate)
10 mg as required 1 0
Bold text indicate “as required” dosages
Abbreviations: EOMD, Equivalent Oral Morphine Dose; PaDSMaP Patient-directed self-management of pain; TAU treatment as usual
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The baseline scores (Table 3) show that overall our
population agreed that medicines were generally not
harmful or overused. The differences between the spe-
cific necessity and concerns scores were positive, which
indicated that these patients perceive that the benefits of
taking medications outweigh the risks.
Of the 68 patients analysed in the PaDSMaP group; 47
started self-medicating (six of whom later stopped (due
to losing competency, n = 7, or anxiety n = 1), and four
who started, stopped and then restarted before the end
of day 3 (due to losing competency n = 3 or anxiety n =
1)), 21 never started (including two who withdrew from
the study; due to losing competency up to day 3 n = 16
or anxiety n = 5), and 41 were classed as having success-
fully completed the self-medicating protocol (Fig. 1).
None of the patients reported any difficulties in opening
the medication lockers, and all keys were kept secure for
the duration of the study.
Self-medicating patients were also in control of their
co-morbid medications. They took a median of 5 (range
0–11) prescriptions. Although at the initiation of the
project we were assured that no patients self-medicated
on the ward, we found that one diabetic patient allocated
to the TAU group did self-medicate with their injectable
insulin. All of their remaining medications were deliv-
ered by the nurses as usual.
Baseline comparison
Little difference was observed between the two groups’
baseline characteristics (Tables 2, 3, 4). More of the
PaDSMaP group were in employment (28% vs 16%) or
had musculoskeletal problems (27% vs 9%), and fewer
scored above the cut off for depression (a HADS depres-
sion score of ≥8) (7% vs 17%) [20].
Primary outcome
No evidence was found for a between group difference
in ITT mean pain score (static VAS for the previous 4 h)
at 72 h/discharge (Table 6). Similar results were obtained
after (i) adjustment by baseline VAS, HADS anxiety,
HADS depression as specified in the statistical analysis
plan and (ii) further adjustment by gender and number
of prescribed medications, identified by the covariate se-
lection procedure (Table 6).
Using the per protocol definition, patients who were
able to self-medicate had significantly lower static VAS
(effect − 9.9 mm, 95% CI -18.7 to − 1.1, T-test) and
mobilised VAS (effect − 13.1 mm, 95% CI-23.8 to − 2.4,
T-test) at 72 h/discharge compared to TAU patients.
Secondary outcomes
Predictors of successful self-medication
Forty-one of 68 patients randomised to self-medicate
were ‘successful’ as defined for the per protocol analysis.
Only one of 30 baseline variables considered individually
showed a significant bivariate association with successful
self-medicating. The number of co-morbidities was sig-
nificantly higher in the group that were unable to self-
medicate (mean 3.6 vs 2.7, p = 0.007 Wilcoxon Mann
Witney).
In an unplanned analysis suggested by the research
nurses, lower static pain scores at day 1 breakfast were a
highly significant predictor of successful self-medication.
(Mean for successful self-medication 44.2 vs 69.2 for
those unable to self-medicate, 95% CI of difference 10.9
to 39.2, P = 0.001, T-test.)
Pain scores
No evidence was found for a between group difference
in ITT mean pain after mobilisation score at 72 h/dis-
charge. No significant between group difference was
found in pain VAS at 6 weeks (Table 6) whether using
ITT or per protocol analysis.
In a repeated measures analysis of all nine static post-
operative pain scores (breakfast, lunch and supper scores
for days 1–3 after the operation, Table 7, Fig. 2) com-
pared between groups, significant day and time-of-day
terms suggested that separate models were appropriate
at different time points. However, no significant diffe-
rence was found between the randomised groups for any
of the nine time points considered individually.
An unplanned ‘three group’, repeated measures ana-
lysis comparing TAU (n = 69), those in PaDSMaP able to
self-medicate (n = 41), and those in PaDSMaP unable to
self-medicate (nurse medicated) (n = 27), indicated a
particularly large effect between those patients that were
unable to self-medicate and TAU on day 1, which re-
duces by day 3, suggesting again that individual pain
time points should be considered separately. The three
groups pain scores were significantly different from each
other at each of breakfast, lunch and supper of day 1, (p =
0.004, 0.009, 0.032 respectively, one-way ANOVA). This
led to an exploratory analysis in which we compared the
primary outcome, static VAS at 72 h/discharge, between
groups, adjusting by day 1 breakfast VAS. This investigates
whether group predicts the primary outcome for those
with the same pain level at breakfast day 1. In the
ITT analysis group this was not significant (− 3.0, 95%
CI -10.9 to 5.0 P = 0.456, T-test), but day 1 breakfast’s
pain score was a strong predictor of the primary out-
come (P = 0.008, T-test).
Other outcomes
No significant between group difference was found in
the time to mobilisation (Table 8). Therefore the ana-
lyses originally planned to compare time to mobilisation
with adverse event frequency, quality of life scores, acti-
vities of daily living scores, and level of pain at 6 weeks
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were not performed. No significant between group dif-
ference was found for ED-5D-3 L or OKS at 6 weeks
(Table 8). We also found no significant between group
difference for satisfaction with pain or information scales
at 3 days/discharge or 6 weeks (Table 8).
Adverse events
During the study one patient in the self-medicating
group took an accidental overdose of morphine sulphate
(Oramorph). The patient had started self-medicating at
lunchtime on day 1 after surgery. On day 2 at 08:15 the
pain team found the patient was a little confused and
unsure what medications he had taken. The prescription
chart had not been filled in accurately and 30 ml of Ora-
morph was unaccounted for. After the overdose, Trust
policies [13] were followed and it was found that it had
resulted in no harm to the patient.
One other patient in the self-medicating group had
a medication error. She had brought in her prescribed
pregabalin and co-codamol 30/500 from home, and
on the morning of day 1 after surgery she started
self-medication and took these medications from her
home pack. However the patient had been prescribed
paracetamol and oxycontin post-operatively. The error
was noticed by 08:30 before the patient was given her
inpatient pack of medications, and oxycontin was
omitted from her morning medication dosage as it
was contraindicated with the co-codamol. The patient
was reassessed for competency to self-medicate and
was assessed as not competent, the medications from
home were removed from her locker and she was
placed back under the care of the ward nurses for
medication delivery which adhered to the hospital
prescribed regimen.
Eight patients stated to the nurses that they were an-
xious about managing to self-medicate after their oper-
ation. Five of these patients never started self-medicating,
one returned to usual nursing care, one stopped but then
re-started self-medicating, one continued self-medicating
with support.
There were no medication errors in the TAU group.
However over the period of the trial 11 other medication
errors occurred on the trial ward in the general patient
population of 276, all of whom had nurse controlled
medication delivery. These errors included missed medi-
cations, incorrect dosage, and incorrect medications.
None resulted in any harm to the patients.
Although we recorded a substantial number of other
adverse events such as confusion, dizziness, nausea, or
vomiting, none of these were determined to be trial-
Table 7 VAS Scores over Days 1–3 After the Operation
Day 1 B Day 1 L Day 1 S Day 2 B Day 2 L Day 2 S Day 3 B Day 3 L Day 3 S
Static VAS
TAU 56.6
(27.5)
N = 68
49.5
(25.3)
N = 66
49.3
(25.1)
N = 62
46.4
(23.6)
N = 64
37.9
(20.1)
N = 61
39.8
(25.2)
N = 58
36.1
(22.4)
N = 60
32.9
(23.8)
N = 54
32.3
(23.2)
N = 43
PaDSMaP 48.6
(31.8)
N = 60
45.6
(29.5)
N = 58
49.7
(27.7)
N = 57
47.1
(26.3)
N = 59
45.1
(28.5)
N = 57
44.7
(27.0)
N = 53
41.8
(26.5)
N = 58
36.9
(26.6)
N = 55
35.8
(25.2)
N = 29
PaDSMaP SM 50.3
(33.4)
N = 36
46.7
(33.1)
N = 36
53.4
(29.8)
N = 36
53.3
(26.3)
N = 35
47.5
(29.3)
N = 34
45.6
(25.6)
N = 32
44.8
(27.7)
N = 35
42.3
(27.3)
N = 34
38.5
(27.2)
N = 12
PaDSMaP NM 45.5
(29.1)
N = 24
38.7
(21.0)
N = 22
41.2
(21.1)
N = 21
37.2
(23.3)
N = 24
41.6
(26.9)
N = 23
43.3
(29.1)
N = 21
37.1
(23.9)
N = 23
28.1
(22.8)
N = 21
31.2
(20.6)
N = 17
VAS after mobilisation
TAU 58.5
(28.1)
N = 51
55.9
(27.9)
N = 52
53.9
(29.8)
N = 44
55.6
(26.4)
N = 58
49.4
(30.3)
N = 51
45.1
(25.7)
N = 41
42.0
(26.3)
N = 51
40.6
(26.9)
N = 43
41.8
(29.3)
N = 33
PaDSMaP 61.2
(27.9)
N = 57
57.4
(23.2)
N = 50
51.7
(20.8)
N = 41
51.7
(23.8)
N = 56
42.7
(23.8)
N = 55
42.2
(23.5)
N = 49
44.2
(24.8)
N = 58
35.4
(25.0)
N = 51
35.8
(25.2)
N = 41
PaDSMaP SM 56.6
(28.5)
N = 36
51.3
(23.1)
N = 32
50.9
(21.3)
N = 26
49.2
(23.2)
N = 39
39.9
(25.1)
N = 37
39.6
(25.1)
N = 33
39.1
(24.5)
N = 38
27.9
(22.4)
N = 34
28.7
(20.5)
N = 26
PaDSMaP NM 69.3
(24.7)
N = 21
68.3
(19.7)
N = 18
53.1
(20.0)
N = 15
57.6
(24.2)
N = 17
48.6
(19.4)
N = 18
47.4
(18.8)
N = 16
53.7
(22.5)
N = 20
50.3
(23.1)
N = 17
50.3
(23.1)
N = 17
Mean (SD)
Abbreviations: D Day, B breakfast 08:00, L lunch 13:00, S supper 17:45, N number of participants, SM self-medicated, NM nurse medicated; PaDSMaP Patient-directed
self-management of pain; TAU treatment as usual
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related by our Data Monitoring Committee, which had
an independent chair. However these symptoms were
the usual reasons given by participants for not self-
medicating within the 3 days after surgery that were
monitored for the study.
Discussion
This is the first ever RCT of patient controlled oral anal-
gesia that allowed for patients to self-medicate with indi-
vidualised poly-pharmacy analgesia protocols and
additionally be in control of their co-morbid medica-
tions, as far as we are aware [36]. Previous studies have
allowed patients to control just one analgesic medication
(liquid morphine or short-acting opioids such as mor-
phine or oxycodone) for short periods of time (8–24 h)
[37–39]. Our protocol ensured that patients were in
charge of all of their analgesics (except for controlled an-
algesics, as required by law) and co-morbid medications
for 3 days after the operation. Our protocol allowed for
individualisation of the pain medications prescribed ac-
cording to patient characteristics, but if the ‘usual’ NERP
protocol was followed [14] then our patients would be
in control of four different oral analgesic medications
(paracetamol, ibuprofen, and gabapentin pills and liquid
morphine sulphate), some of which would be new to
them. Additionally, in this trial, these new medications
were being taken by medically complex elderly patients.
These patients are more representative of modern hos-
pital populations [40] than the more selected patient
populations represented in previous RCTs [37–39].
The ITT analysis showed that the pain levels of pa-
tients allocated to self-medicate were not superior to
those whose medications were dispensed by ward nurses
at 3 days/discharge (primary endpoint). Per protocol
analysis of the 60% who managed to self-medicate
showed that they had reduced levels of pain, however
this analysis was underpowered so must be regarded
with caution. The size of pain reduction was similar to
that shown by meta-analyses of PCA trials [8]. This sug-
gests that the key issue to improve pain levels is who is
in control of the analgesia, rather than the method used
to facilitate this. It may be that being in control of their
analgesia may increase a patient’s psychological resili-
ence and preparedness for painful stimuli. This, in turn,
Fig. 2 VAS Scores over Days 1–3 After the Operation
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may reduce the emotional component of pain and so
make it easier to control [18, 41]. Greater autonomy
over pain relief has been linked to improved dignity and
patient experience [42, 43]. In turn these factors have
been linked to better medication adherence [44].
Greater pain on day 1 after the operation and more
co-morbidities predicted those who were unable to self-
medicate. This suggests that those with more pain do
not start self-medicating or may stop self-medicating.
Those patients with higher numbers of co-morbidities
may be less well after their operations, thus preventing
them from being able to self-medicate.
Since 21% of patients who started self-medicating were
unable to continue self-medicating (either temporarily or
permanently) within the 3 days after the operation due to
confusion, dizziness or vomiting, it highlights the import-
ance of on-going assessment of the patient’s wellbeing and
competency to self-medicate by the nurses on their usual
drug rounds. Although there are some risks from over-
medication, this appears to happen infrequently. As far as
we are aware this is the first time an overdose has been
reported in an oral self-medicating RCT, with a total of
127 self-medicating patients [37–39]. It should be remem-
bered that nurse-mediated medication delivery is not
completely risk free. Thus, as with any medication proto-
col, risk management is essential. In the case of self-
medication it is likely that good patient selection, and
training and support of both patients and staff should
mitigate this risk to within acceptable levels.
Considering the small pain score differences and the
emphasis placed on early mobilisation in the NERP
protocol [14], it was unsurprising that the time to mobil-
isation showed no difference between the two groups.
No difference was identified between the groups for
quality of life, activities of daily living, satisfaction with
information and satisfaction with pain. This may be due
to the short duration of impact of the self-medication on
global issues such as health-related quality of life or ac-
tivities of daily living, as these were only measured at
baseline and 6 weeks. Both groups received information
on their TKR operation, whilst the PaDSMaP group re-
ceived further information on self-medication, it may be
that this was not enough to improve satisfaction with in-
formation. Satisfaction with pain has been identified
elsewhere [28] as a complex construct that is not solely
dependent on pain levels. Both groups were in receipt of
individualised pain medication protocols, optimised
according to evidence and patient characteristics. So al-
though we detected differences between the groups’ pain
levels, it did not change the satisfaction with pain
control.
The highly specialist Pharmacists on the ward did pre-
pare the drug packs and drug charts for each patient,
and the research nurses conducted the two training
Table 8 ITT group analysis of secondary outcomes
Outcome PaDSMaP Mean (sd) TAU Mean (sd) Estimated effecta (95% CI)
(linear model, T-test)
Difference (95% CI) Adjusted by baselineb,
HADS anxiety, HADS depression (linear
model, T-test)
Time to
Mobilisation
36.1 (23.4)
n = 65
34.4 (21.4)
n = 66
1.7(− 6.0,9.5)
P = 0.661
2.8(− 5.1,10.7)
P = 0.486
Intention to Treat
analysis
SWP Baseline 8.87 (2.3)
n = 69
8.09 (2.5)
n = 68
SWP 3 days 9.52 (2.6) n = 53 9.77 (2.7)
n = 53
−0.245 (−1.3,0.77)
p = 0.634
− 0.30 (− 1.36,0.77)
n = 106
p = 0.578
SWP 6 weeks 10.8 (2.8)
n = 63
11.0 (3.2)
n = 66
− 0.191 (− 1.2,0.86)
p = 0.719
−0.25 (− 1.34,0.84)
n = 127
p = 0.647
SWI 3 days 30.1 (9.6)
n = 48
31.8 (9.5)
n = 54
−1.68 (−5.44,2.08)
p = 0.379
−1.76 (− 5.58,2.07)
n = 101
p = 0.365
SWI 6 weeks 28.2 (10.6)
n = 61
32.1 (13.5)
n = 61
−3.87 (− 8.1,0.64)
p = 0.093
−4.34 (− 8.87,-0.03)
n = 120
p = 0.048c
OKS Baseline 19.0 (7.1) 18.8 (7.2)
OKS 6 weeks 28.2 (7.2) 27.6 (8.0) 0.55 (−2.1, 3.2)
p = 0.680
0.486 (−2.1,3.1)
n = 130
p = 0.710
aEstimated treatment effect of self-medication compared to TAU
bCorresponding baseline outcome or (for SWI), VAS baseline
cAnxiety is highly significant here P = 0.004 and reduces predicted SWI
Abbreviations: HADS – Hospital Anxiety and Depression Scale; ITT – intention to treat; OKS – Oxford Knee Scale; PaDSMaP - Patient-directed self-management of
pain; SWP – Satisfaction With Pain scale; SWI – Satisfaction With Information scale; TAU – treatment as usual
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sessions. Therefore if this protocol was adopted more
generally, workload changes would have to be evaluated.
Strengths and limitations of this study
The population selected were elderly, had co-
morbidities, and the operation required a high level of
opiates in order to control pain levels suitably. All of
these factors led to a high incidence of adverse events
such as confusion, dizziness or vomiting post-operatively,
which were the usual reasons for patients not self-
medicating. As 40% of patients were unable to complete
the self-medicating protocol, the study was effectively
under-powered.
The high rate of co-morbidities in our population was
due to ASA grade 1 patients (being healthy with a well-
controlled co-morbidity [34]) generally being referred to
a private healthcare provider which was not involved in
the study. This high rate of co-morbidities limits the
generalisability of our results to populations with low or
no co-morbidities. However our data suggest that these
populations would be more likely to manage a self-
medicating protocol.
Obviously only patients willing to participate in the
trial were recruited. Many of those who refused stated
that they were concerned about their ability to manage
the perceived complexity of self-medication after an
operation. Overall our participants had more positive be-
liefs regarding the benefits of taking medications when
compared to other chronic conditions [21]. Therefore if
self-medication was rolled out for all eligible patients,
further time might be needed to ensure concerns about
the medicines and self-medicating were addressed to pa-
tient’s satisfaction.
There was rarely more than one self-medicating pa-
tient on the ward at any one time. Sawhney [45] showed
that professionals’ knowledge and confidence in self-
medicating improved with time and numbers of patients
treated. Therefore it is likely that having a greater
number of self-medicating patients would have im-
proved understanding and embedded the protocols with
ward staff.
There were a few missing pain scores, mostly in the
intermediate time points. We know that at least some of
these scores were missing due to patients’ unwillingness
to complete the research outcomes when they were in
severe pain i.e. they were not missing at random. There-
fore the intermediate time point’s pain scores may have
been under-estimated.
Due to the trial allowing patients to be prescribed
individualised analgesia, it is impossible to compare the
analgesic “dose” between the groups. Patients were
prescribed a range of analgesics. Although the daily
Equivalent Oral Morphine Dose (EOMD) could be esti-
mated [35], it would not fairly represent the analgesia
provided. Patients usually received additional non-opioid
analgesics which have been shown to improve quality of
analgesia and reduce opioid use [9–11]. There are cur-
rently no methods that allow for the calculation of an
overall analgesic dose that includes both opioid and
non-opioid analgesics, and even the EOMD estimates
are not without controversy and variations in how they
are calculated [46].
Comparison with other studies
As noted in our introduction the evidence base is lim-
ited and not consistent. Striebel’s two studies [38, 39]
claimed PCOA increased patient satisfaction and pain
control compared to patient controlled intravenous
analgesia, and Kastanias’ study [37] showed no difference
between PCOA and nurse-controlled analgesia on day 2
after a TKR.
Implications of findings and future research
Currently elective surgical patients have all their
inpatient medications controlled by healthcare profes-
sionals, yet patients are expected to manage to self-
medicate once they are discharged home. For patients
capable of self-medication there are potential benefits in
terms of improved pain control. However this study
demonstrated that self-medication was not suitable for
all and a patient’s ability to self-medicate needs to be
assessed on an on-going basis. The factors which may
limit the ability of adults to self-medicate include having
high pain levels on day 1, having higher numbers of co-
morbidities, and suffering from adverse events of the
surgery and anaesthesia such as confusion and nausea.
Our cost effectiveness analysis [30] showed that the
additional costs of self-medication were not large, par-
ticularly once set-up costs are accounted for. The calcu-
lation of the self-medicating group’s health related costs
was complicated by four self-medicating patients requir-
ing periods of time in intensive care (for reasons unre-
lated to their self-medicating). A longer period of
evaluation with a larger cohort would give a clearer
picture on the costs of a self-medicating protocol.
We are aware that there are significant political
pressures on hospitals to implement self-medicating pol-
icies in order to improve patients’ autonomy and dignity
[36, 47–50]. The hospital in which this research was
conducted now has a target of having all suitable inpa-
tients self-medicating. This study supports this target
but highlights that there are significant training needs
for both staff and patients. Additionally organisational
aspects, such as the availability of Specialist Ward Phar-
macists and secure accessible patient lockers, are re-
quired to ensure the safe and successful implementation
of this policy.
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Further research is needed to identify how important
this reduction in pain and improvement in autonomy is
to patients; whether it is worth the additional training
time needed for staff and patients; or if the implementa-
tion of self-medication should be for all eligible patients
in inpatient settings, and finally, and the evaluation of
the health economic implications. The risks of the
protocol need to be quantified and management proto-
cols developed that include the development of predict-
ive tools to identify patients unlikely to manage self-
medication. Finally the development of a method to cal-
culate the overall analgesic dose for patients prescribed
combinations of opioid and non-opioid medications
would be helpful.
Conclusion
This is the first randomised controlled trial of patient
controlled oral analgesia that examined individualised
multi-medication analgesia. It compared the usual
delivery of pharmacological analgesia by nurse-led
rounds with patients self-medicating with their drugs
held in special locked bed-side cabinets. The self-
medicating patients (PaDSMaP) had pain scores that
were not superior to the nurse-managed patients (TAU).
However 40% of those allocated to self-medication were
not able to self-medicate. The 60% that were able to
self-medicate had lower pain scores than those managed
by nurse-managed care. This cohort of patients were
elderly with multiple co-morbidities and may not be the
ideal target group for self-medication.
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